Buy this company before the earnings announcement. This will be their first quarter of steady positive earnings (actually their second positive quarter ever). The stock is down a lot over the past couple of years, but now the company is actually… More
The company appears to be relying on collaborations with big pharma, which sends me a signal that it will stay small and only marginally profitable if at all. It expects only modest growth of its product Fuzion, despite the fact that an HIV targeted… More